Shigeki Hibi
Research Subjects
Shigeki Hibi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Hiroyuki Yoshimura
Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan
1 shared publicationKenji Tai
Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan
1 shared publicationKouichi Kikuchi
Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan
1 shared publicationMitsuo Nagai
Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan
1 shared publicationTakayuki Hida
Tsukuba Basic Research Laboratories, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki, 300-26, Japan
1 shared publication
Latest Publications
- 25 July 1998
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (17) , 3245-3252
Syntheses and Structure−Activity Relationships of Novel Retinoid X Receptor Agonists
As part of our studies to develop novel retinoids with increased affinity and selectivity for the retinoid X receptor (RXR) subfamily, we have designed and synthesized a series of (E,E,E)-7-(1,2,3, 4-tetrahydroquinolin-6-yl)-7-alkyl-6-fluoro-3-methylhepta-2, 4, 6-trienoic acid derivatives. These tetrahydroquinolines, generated by introducing a polar N atom into the hydrophobic part of the retinoid skeleton, showed high binding affinity to RXRs. Addition of fluorine at the 6-position of the 2,4,6-trienoic acid moiety afforded compounds which elicit potent and selective transactivation of the RXRs. Compound 14b (ER-35794), which possesses an ethyl substituent at the 7-position and fluorine at the 6-position of the triene moiety, is one of the most potent and selective RXR agonists reported to date.
- 25 July 1998
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (17) , 3245-3252
Syntheses and Structure−Activity Relationships of Novel Retinoid X Receptor Agonists
As part of our studies to develop novel retinoids with increased affinity and selectivity for the retinoid X receptor (RXR) subfamily, we have designed and synthesized a series of (E,E,E)-7-(1,2,3, 4-tetrahydroquinolin-6-yl)-7-alkyl-6-fluoro-3-methylhepta-2, 4, 6-trienoic acid derivatives. These tetrahydroquinolines, generated by introducing a polar N atom into the hydrophobic part of the retinoid skeleton, showed high binding affinity to RXRs. Addition of fluorine at the 6-position of the 2,4,6-trienoic acid moiety afforded compounds which elicit potent and selective transactivation of the RXRs. Compound 14b (ER-35794), which possesses an ethyl substituent at the 7-position and fluorine at the 6-position of the triene moiety, is one of the most potent and selective RXR agonists reported to date.